Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NASDAQ:RGDX
- CUSIP: N/A
- Web: www.responsegenetics.com/
- 50 Day Moving Avg: $0.17
- 200 Day Moving Avg: $0.34
- 52 Week Range: $0.01 - $0.85
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.17
- P/E Growth: 0.000
- Net Margins: -106.01%
- Return on Assets: -133.08%
- Average Volume: 286,022 shs.
Frequently Asked Questions for Response Genetics (NASDAQ:RGDX)
What is Response Genetics' stock symbol?
Response Genetics trades on the NASDAQ under the ticker symbol "RGDX."
How were Response Genetics' earnings last quarter?
Response Genetics, Inc. (NASDAQ:RGDX) posted its quarterly earnings results on Tuesday, March, 31st. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $4.10 million for the quarter. View Response Genetics' Earnings History.
Who are some of Response Genetics' key competitors?
Some companies that are related to Response Genetics include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI), Hikma Pharmaceuticals Plc (HIK) and WuXi PharmaTech (Cayman) (WX).
Who are Response Genetics' key executives?
Response Genetics' management team includes the folowing people:
- Thomas A. Bologna, Chairman of the Board, Chief Executive Officer
- Kevin Roy Harris, Chief Financial Officer, Vice President
- Adanech Getachew, General Counsel
- Kirk K. Calhoun, Lead Independent Director
- Michael Serruya, Director
- Sam Chawla, Independent Director
- David R Schreiber, Independent Director
- Richard A. van den Broek, Independent Director
How do I buy Response Genetics stock?
Shares of Response Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Response Genetics' stock price today?
MarketBeat Community Rating for Response Genetics (NASDAQ RGDX)MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Response Genetics stock can currently be purchased for approximately $0.03.
Consensus Ratings for Response Genetics (NASDAQ:RGDX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Response Genetics (NASDAQ:RGDX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Response Genetics (NASDAQ:RGDX)Earnings History by Quarter for Response Genetics (NASDAQ RGDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/14/2015||Q115||($0.10)||$3.90 million||$3.80 million||View||Listen|
|8/14/2014||Q214||($0.08)||$3.90 million||$4.30 million||View||N/A|
|5/8/2014||Q114||($0.06)||($0.03)||$5.50 million||$3.90 million||View||N/A|
|3/20/2014||Q413||($0.07)||($0.09)||$5.30 million||$4.80 million||View||N/A|
|11/7/2013||Q313||($0.07)||($0.08)||$5.40 million||$4.10 million||View||N/A|
|8/8/2013||Q2 2013||($0.04)||($0.11)||$5.40 million||$5.30 million||View||N/A|
|5/14/2013||Q1 2013||($0.04)||($0.03)||$4.92 million||$5.60 million||View||N/A|
|11/13/2012||Q312||($0.07)||($0.05)||$4.50 million||$5.40 million||View||N/A|
Earnings Estimates for Response Genetics (NASDAQ:RGDX)
Current Year EPS Consensus Estimate: $-0.190 EPS
Next Year EPS Consensus Estimate: $-0.150 EPS
Dividend History for Response Genetics (NASDAQ:RGDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Response Genetics (NASDAQ:RGDX)
Latest Headlines for Response Genetics (NASDAQ:RGDX)
|New Peer-Reviewed Clinical Study Successfully Validates The Use Of Proove Opioid Risk® To Predict Prescription Opioid Abuse|
www.bizjournals.com - May 12 at 1:00 AM
|Should Biotech Investors Worry About Donald Trump?|
www.zacks.com - December 8 at 7:57 PM
|RESPONSE GENETICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Change in Directors or|
biz.yahoo.com - October 14 at 6:03 AM
|RESPONSE GENETICS INC Files SEC form 8-K, Other Events|
biz.yahoo.com - October 5 at 4:22 PM
|RESPONSE GENETICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand|
biz.yahoo.com - August 26 at 6:02 AM
|RESPONSE GENETICS INC Financials|
finance.yahoo.com - August 14 at 1:04 PM
|RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Cre|
biz.yahoo.com - August 11 at 2:44 PM
|Cancer Genetics to Acquire Assets of Response Genetics|
finance.yahoo.com - August 10 at 1:55 PM
|RESPONSE GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial|
biz.yahoo.com - July 1 at 4:07 PM
|Great Basin Welcomes Kirk Calhoun to Board of Directors|
finance.yahoo.com - June 2 at 8:00 AM
|RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - May 15 at 4:55 PM
|RESPONSE GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh|
biz.yahoo.com - May 14 at 7:31 AM
Response Genetics (RGDX) Chart for Thursday, July, 20, 2017